| P50 | author | Ming-Hua Zheng | Q37831296 |
| | Gui-qi Zhu | Q42757517 |
| | Keqing Shi | Q59704601 |
| P2093 | author name string | Ji-Na Zheng | |
| | Tian-Tian Zou | |
| | Da-Zhi Chen | |
| | Zhuo-Lin Zou | |
| P2860 | cites work | High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q24655731 |
| | Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis | Q26824664 |
| | Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer | Q26864932 |
| | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860749 |
| | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis | Q28087211 |
| | Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 |
| | The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Q29616215 |
| | Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 |
| | Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection | Q29620338 |
| | Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis | Q29620612 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial | Q33600403 |
| | Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study | Q33956796 |
| | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial | Q34038836 |
| | Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression | Q34083354 |
| | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial | Q34649453 |
| | Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection | Q34777639 |
| | Treatment of hepatitis C: a systematic review | Q35223637 |
| | Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy | Q35561845 |
| | Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis | Q35660038 |
| | A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. | Q35778052 |
| | Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 |
| | Evidence synthesis for decision making 1: introduction | Q36991738 |
| | Use of indirect and mixed treatment comparisons for technology assessment | Q37259556 |
| | Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases | Q38311380 |
| | Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses | Q39735046 |
| | Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States | Q40249402 |
| | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis | Q41258325 |
| | STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection | Q41563622 |
| | A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. | Q41605573 |
| | Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials | Q41822229 |
| | Antiviral treatment of hepatitis C. | Q42207125 |
| | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial | Q42211652 |
| | Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial | Q42224933 |
| | Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. | Q42241885 |
| | A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection | Q42241890 |
| | Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection | Q42276777 |
| | Faldaprevir and deleobuvir for HCV genotype 1 infection. | Q42276796 |
| | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 |
| | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial | Q42981494 |
| | Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial | Q42986599 |
| | Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 |
| | Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. | Q42988738 |
| | Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study | Q43036320 |
| | A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 |
| | The global health burden of hepatitis C virus infection | Q45365903 |
| | High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study | Q46802343 |
| | Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. | Q50569800 |
| | Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. | Q50618802 |
| | On the Complexity of Additive Clustering Models. | Q52068544 |
| | Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 |
| | Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 |
| P275 | copyright license | Creative Commons Attribution-NoDerivs 4.0 International | Q36795408 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| | systematic review | Q1504425 |
| | RNA virus infectious disease | Q18967413 |
| | antiviral agent | Q40207875 |
| | chronic hepatitis C | Q55779873 |
| P304 | page(s) | e3004 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Medicine | Q15716652 |
| | Medicine (Barcelona) / Programa de Educación Médica Continuada (EMC) en medicina Asistencial | Q29044007 |
| P1476 | title | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 | |
| P478 | volume | 95 | |